MACULAR DEGENERATION TREATMENT MARKET ANALYSIS

Macular Degeneration Treatment Market, By Type (Dry Age-related Macular Degeneration and Wet Age-related Macular Degeneration), By Stage Of Disease (Early-stage AMD, Intermediate AMD, and Late-stage AMD), By Route Of Administration (Intravenous Route and Intravitreal Route), By Sales Channel (Ambulatory Surgical Centres, Hospitals, and Other Sales Channels), and By Geography (North America Europe, Asia-Pacific, South America, and Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Aug 2022
Code : CMI5149
Pages :174
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Recent Developments:

In February 2021, Roche announced detailed results from phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema and neovascular or wet age-related macular degeneration (nAMD).

In February 2020, Novartis received a European Commission approval for marketing of Beovu. It is an anti-VEGF agent used for treating wet-AMD patients.

Macular Degeneration Treatment Market Report Snapshots